Robert Lutz - IBio, Common Chief Officer
| IBIO Stock | USD 4.56 0.17 3.87% |
Insider
Robert Lutz is Chief Officer of iBio, Common Stock
| Age | 55 |
| Address | 11750 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 979 446 0027 |
| Web | https://ibioinc.com |
IBio, Common Management Efficiency
The company has return on total asset (ROA) of (0.2973) % which means that it has lost $0.2973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8415) %, meaning that it created substantial loss on money invested by shareholders. IBio, Common's management efficiency ratios could be used to measure how well IBio, Common manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, IBio, Common's Total Assets are very stable compared to the past year. As of the 21st of March 2025, Non Current Assets Total is likely to grow to about 17.9 M, while Other Current Assets are likely to drop about 818.3 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Elliott Berger | BioCryst Pharmaceuticals | N/A | |
| CPA CPA | Tonix Pharmaceuticals Holding | 50 | |
| David Sesin | Jaguar Animal Health | N/A | |
| Dr DPS | ADMA Biologics | 77 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Seth MD | Tonix Pharmaceuticals Holding | 67 | |
| CPA MBA | Vaxart Inc | 72 | |
| Kaitlin Kestenberg | ADMA Biologics | 37 | |
| Michael Shine | Ocugen Inc | N/A | |
| Robert McRae | Palisade Bio | N/A | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Mark Newman | GeoVax Labs | 70 | |
| Cezar MBA | Vaxart Inc | 51 | |
| William MBBS | BioCryst Pharmaceuticals | 70 | |
| Dr Stapleton | Vaxart Inc | 53 | |
| Brant Biehn | Vaxart Inc | N/A | |
| Fuad Ahmad | Vaxart Inc | 54 | |
| Vijay Tammara | Ocugen Inc | 64 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| CPA CPA | Ocugen Inc | 47 | |
| Stephanie Angelini | BioCryst Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.3 |
iBio, Common Stock Leadership Team
Elected by the shareholders, the IBio, Common's board of directors comprises two types of representatives: IBio, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IBio,. The board's role is to monitor IBio, Common's management team and ensure that shareholders' interests are well served. IBio, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IBio, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Middlebrook, Chief Officer | ||
| Stephen Kilmer, Investor Officer | ||
| Marc JD, General Counsel | ||
| Melissa Berquist, VP Health | ||
| Robert Lutz, Chief Officer | ||
| Robert Kay, Executive Chairman and CEO | ||
| Dr DVM, Chief Officer | ||
| Mike Jenkins, VP Operations | ||
| Thomas III, Pres CEO | ||
| Randy Maddux, Strategic Advisor | ||
| Kristi Sarno, Senior Development | ||
| Felipe Duran, Chief Officer | ||
| Nick DeLong, VP Devel |
IBio, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IBio, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (19.48) % | ||||
| Current Valuation | 40.33 M | ||||
| Shares Outstanding | 9.14 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 31.92 % | ||||
| Number Of Shares Shorted | 307.8 K | ||||
| Price To Earning | (2.18) X | ||||
| Price To Book | 3.12 X |
Pair Trading with IBio, Common
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IBio, Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IBio, Common will appreciate offsetting losses from the drop in the long position's value.Moving against IBio, Stock
| 0.84 | CLDX | Celldex Therapeutics | PairCorr |
| 0.84 | GKOS | Glaukos Corp | PairCorr |
| 0.78 | SNDL | SNDL Inc | PairCorr |
| 0.71 | EYEN | Eyenovia | PairCorr |
| 0.67 | CRNX | Crinetics Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to IBio, Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace IBio, Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back IBio, Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iBio, Common Stock to buy it.
The correlation of IBio, Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as IBio, Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iBio, Common Stock moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for IBio, Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.